

Initial REMS approval: 07/23/2014
Most recent modification: 03/2018

NDA 205858

ZYDELIG® (idelalisib) tablets

Drug Class: Phosphoinositide-3 Kinase-Delta Inhibitor

Gilead Sciences, Inc.
333 Lakeside Drive
Foster City, CA 94404
Phone: (800) 445-3235

RISK EVALUATION AND MITIGATION STRATEGY (REMS)

I. GOAL:

The goal of the Zydelig REMS is to mitigate the risks of fatal and /or serious hepatotoxicity; fatal and/or serious and severe diarrhea or colitis; fatal and/or serious pneumonitis; fatal and/or serious infections, and fatal and serious intestinal perforation associated with Zydelig treatment by informing healthcare providers of the risks of

- fatal and/or serious hepatotoxicity
- fatal and/or serious and severe diarrhea or colitis
- fatal and/or serious pneumonitis
- fatal and/or serious infections
- fatal and serious intestinal perforation

II. REMS ELEMENTS

A. Communication Plan

Gilead Sciences, Inc. (Gilead) must implement the following communication plan for healthcare providers who are likely to prescribe Zydelig. The communication plan must consist of the following:

- 1. REMS Letter Healthcare Providers - A *REMS Letter to Healthcare Providers* must be distributed within 30 calendar days of the approval of the REMS modification (01/26/2018). The letter must be distributed electronically to oncologists and hematologists who are likely to prescribe Zydelig. If a targeted healthcare provider's**

email address is not available, or if an email is undeliverable, the provider will receive the letter through the mail. The *REMS Letter to Healthcare Providers* must inform healthcare providers of the risks of fatal and/or serious hepatotoxicity; fatal and/or serious and severe diarrhea or colitis; fatal and/or serious pneumonitis; fatal and/or serious infections; and fatal and serious intestinal perforation associated with Zydelig treatment. The letter must be accompanied by the Prescribing Information (with Medication Guide attached) and the *Zydelig REMS Fact Sheet*. The *REMS Letter to Healthcare Providers* must be available from the *Zydelig REMS Website* at the time of distribution and remain on the website for 12 months after approval of the REMS modification (01/26/2018).

- 2. REMS Letter for Professional Societies** - A *REMS Letter for Professional Societies* must be distributed electronically within 30 calendar days of the approval of the REMS modification (01/26/2018). If a targeted Professional Society's email address is not available, or if an email is undeliverable, the letter must be sent through the mail. The *REMS Letter for Professional Societies* must inform the leadership of the professional societies described below of the risks of fatal and/or serious hepatotoxicity; fatal and/or serious and severe diarrhea or colitis; fatal and/or serious pneumonitis; fatal and/or serious infections; and fatal and serious intestinal perforation associated with Zydelig treatment. Gilead must request the leadership of the professional societies distribute this risk information to their memberships.

The *REMS Letter for Professional Societies* must be distributed to the following organizations:

- American Society of Clinical Oncology (ASCO)
- American Society of Hematology (ASH)
- Oncology Nursing Society (ONS)
- National Comprehensive Cancer Network (NCCN)
- Hematology Oncology Pharmacy Association (HOPA)
- American Pharmacists Association (APhA)
- American Society of Health-System Pharmacists (ASHP)

- 3. REMS Fact Sheet** – A *Zydelig REMS Fact Sheet* must be distributed to Healthcare Providers. The *Zydelig REMS Fact Sheet* must be included in the mailings of the *REMS Letter to Healthcare Providers* and the *REMS Letter for Professional Societies* and must be available on the *Zydelig REMS Website*. Hard copies of the *Zydelig REMS Fact Sheet* must also be distributed by Gilead's sales representatives and medical field-based personnel to healthcare providers during follow-up details/visits with healthcare providers for the first 12 months after the approval of the REMS modification (01/26/2018). Gilead sales representatives and medical field-based personnel must orally review the risk messages contained in the *Zydelig REMS Fact Sheet* during the visit with the healthcare provider.
- 4. Journal Information Piece** - Gilead must publish in the following professional journals an information piece that includes the risks of fatal and/or serious hepatotoxicity, fatal

and/or serious and severe diarrhea or colitis, fatal and serious pneumonitis and serious intestinal perforation associated with Zydelig treatment.

- Journal of Clinical Oncology
- Blood
- New England Journal of Medicine
- Hematology Oncology Today
- Oncology & Hematology Review
- Leukemia and Lymphoma

The information piece will be published quarterly in each publication for one year following the REMS modification (01/26/2018).

- 5. Dissemination of REMS information at scientific meetings** – The *Zydelig REMS Fact Sheet* and the Prescribing Information must be prominently displayed at scientific meetings where Gilead has a presence (e.g., booth) through the end of January 2019.
- 6. REMS Program Website** –The *Zydelig REMS Program Website* (www.zydeligrems.com) will continue for 12 months after the approval of this REMS modification (01/26/2018). The *Zydelig REMS Program Website* must include the option to print the currently approved Prescribing Information, Medication Guide, *REMS Letter for Healthcare Providers*, *REMS Factsheet*, and *Patient Safety Information Card*. The Zydelig product website must include a prominent REMS-specific link to the *Zydelig REMS Program Website*. All website information must be updated within 60 calendar days of approval of the REMS modification (01/26/2018).
- 7. Zydelig Patient Safety Information Card** - A Patient Safety Information Card highlights the risks of Zydelig and includes information on the management of these risks. Gilead’s sales representatives or medical field based personnel must distribute the *Patient Safety Information Cards* to prescribers within the first 12 months of approval of the REMS modification (01/26/2018). The *Patient Safety Information Card* must also be available on the Zydelig REMS Program Website for 12 months after the approval of the REMS modification (01/26/2018).

The following are part of the REMS and are appended.

- *REMS Letter to Healthcare Providers*
- *REMS Letter for Professional Societies*
- *REMS Fact Sheet*
- *Journal Information Piece*
- *Zydelig REMS Website*
- *Zydelig Patient Safety Information Card*

B. Timetable for Submission of Assessments

Gilead must submit REMS assessments to the FDA 18 months, 4 years, and 7 years from the date of the initial approval of the REMS (07/23/2014). To facilitate inclusion of as much information as possible while allowing reasonable time to prepare the submission, the reporting interval covered by each assessment should conclude no earlier than 60 calendar days before the submission date for that assessment so that it will be received by the FDA on or before the due date.